Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 3:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 3,004 matching trials from the live ClinicalTrials.gov search.
Filters: "metabolic syndrome" Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Metabolomics and Genetic Diagnosing Pancreatic Neuroendocrine Tumors in MEN1 Patients

NCT03048266
View directory record Official record
Conditions
Multiple Endocrine Neoplasia
Interventions
Not listed
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
629 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 23, 2019 · Synced Oct 16, 2026, 3:21 AM EDT
Completed Phase 2 Interventional Results available

Pioglitazone to Treat Fatty Liver in People With HIV Infection

NCT00441272
View directory record Official record
Conditions
HIV Infections, Hepatic Steatosis, Insulin Resistance
Interventions
Pioglitazone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 19, 2010 · Synced Oct 16, 2026, 3:21 AM EDT
Completed Phase 2 Interventional

A Mechanistic Study of the Effects of LY518674 on High-Density Lipoprotein Cholesterol (HDL-C) Metabolism

NCT00327002
View directory record Official record
Conditions
Metabolic Syndrome X
Interventions
LY518674
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 11, 2015 · Synced Oct 16, 2026, 3:21 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Identifying and Caring for Individuals With Inherited Cancer Syndrome

NCT04494945
View directory record Official record
Conditions
BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome, Breast Ductal Carcinoma In Situ, Hematopoietic and Lymphoid System Neoplasm, Hereditary Neoplastic Syndrome, Lynch Syndrome, Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Genetic Counseling, Genetic Testing, Survey Administration
Procedure · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
27,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 16, 2026, 3:21 AM EDT
Completed Phase 2 Interventional Results available

Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients

NCT00110266
View directory record Official record
Conditions
Myelodysplastic Syndrome, Iron Overload
Interventions
Deferasirox
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Concord, California + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Oct 16, 2026, 3:21 AM EDT
Terminated No phase listed Observational

MPS II Immunophenotyping

NCT04976231
View directory record Official record
Conditions
MPS II, Mucopolysaccharidosis II, Hunter Syndrome
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 16, 2026, 3:21 AM EDT
Completed Phase 3 Interventional

Atazanavir or Boosted Atazanavir Substitution for Ritonavir Boosted PI in Patients With Hyperlipidemia

NCT00160329
View directory record Official record
Conditions
Hyperlipidemia, HIV Infections
Interventions
Atazanavir
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2011 · Synced Oct 16, 2026, 3:21 AM EDT
Completed Not applicable Interventional

Role of Aging and Individual Variation in Exercise Training Responsiveness

NCT06471569
View directory record Official record
Conditions
Prediabetic State, Cardiovascular Diseases, Insulin Resistance, Obesity
Interventions
Low/Mod, High/Mod, High/Vig
Behavioral
Lead sponsor
Duke University
Other
Eligibility
60 Years to 90 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 16, 2026, 3:21 AM EDT
Withdrawn Not applicable Interventional

Cholestanol in Humans

NCT00018694
View directory record Official record
Conditions
Cerebrotendinous Xanthomatosis
Interventions
Chenodeoxycholic Acid
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
5 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
1
States / cities
East Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 14, 2013 · Synced Oct 16, 2026, 3:21 AM EDT
Completed No phase listed Observational

Treatment Study of Frontotemporal Dementia

NCT00088751
View directory record Official record
Conditions
Frontotemporal Lobar Degeneration
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
45 Years to 95 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 16, 2026, 3:21 AM EDT
Completed Not applicable Interventional Results available

iSTEP - an mHealth Physical Activity and Diet Intervention for Persons With HIV

NCT03123731
View directory record Official record
Conditions
HIV/AIDS
Interventions
Control Arm, iSTEP
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 16, 2026, 3:21 AM EDT
Recruiting Not applicable Interventional

Cerebellar TMS and Satiety in Prader-Willi Syndrome

NCT05938543
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Repetitive Transcranial Magnetic Stimulation (rTMS)
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 16, 2026, 3:21 AM EDT
Not listed Not applicable Interventional

C15:0 Supplementation in Young Adults at Risk for Metabolic Syndrome

NCT04947176
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Supplement, Placebo
Dietary Supplement · Other
Lead sponsor
Jeffrey B. Schwimmer, MD
Other
Eligibility
18 Years to 25 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 16, 2026, 3:21 AM EDT
Completed Not applicable Interventional

Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities

NCT00015691
View directory record Official record
Conditions
HIV Infections, Lipodystrophy, Hyperinsulinemia
Interventions
Metformin hydrochloride, Rosiglitazone maleate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
34
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2013 · Synced Oct 16, 2026, 3:21 AM EDT
Completed Not applicable Interventional

Effects of Walnuts on Endothelial Function in Overweight Adults With at Least One Factor of Metabolic Syndrome

NCT01413646
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Walnut Supplementation, No walnut supplementation
Dietary Supplement
Lead sponsor
Griffin Hospital
Other
Eligibility
25 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Derby, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 2, 2019 · Synced Oct 16, 2026, 3:21 AM EDT
Terminated Phase 3 Interventional

Ppar-Gamma EliminAtes Restenosis Longevity Study: PEARLS

NCT00465296
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
rosiglitazone
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 22, 2008 · Synced Oct 16, 2026, 3:21 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Use of Pulsatile Intravenous FSH to Mitigate Reprometabolic Syndrome

NCT06414096
View directory record Official record
Conditions
Infertility, Obesity, Diminished Ovarian Reserve (DOR), Diminished Ovarian Reserve
Interventions
Follicle Stimulating Hormone
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
19 Years to 37 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2032
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 16, 2026, 3:21 AM EDT
Completed Phase 1 Interventional

The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists

NCT03049462
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Mirabegron, B Complex Plus Vitamin C Tablets
Drug · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 40 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 16, 2026, 3:21 AM EDT
Completed Not applicable Interventional

Restrictive Intravenous Fluids Trial in Sepsis

NCT03137446
View directory record Official record
Conditions
Septic Shock, Severe Sepsis
Interventions
Intravenous Fluid Cap
Other
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 16, 2026, 3:21 AM EDT
Completed Not applicable Interventional

Effect of a Low Advanced Glycation End Products (AGE) Diet in the Metabolic Syndrome

NCT01363141
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Regular AGE Diet, Low AGE Diet
Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
50 Years and older
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 8, 2015 · Synced Oct 16, 2026, 3:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

FGF21 and Fructose Challenge in Humans

NCT02884791
View directory record Official record
Conditions
Fasting
Interventions
oral carbohydrate challenge
Dietary Supplement
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 16, 2026, 3:21 AM EDT
Not listed Phase 4 Interventional

Effect of Intravenous Acetadote on Incidence of Contrast Induced Nephropathy

NCT00939913
View directory record Official record
Conditions
Nephropathy
Interventions
intravenous NAC, Placebo
Drug
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 18, 2009 · Synced Oct 16, 2026, 3:21 AM EDT
Completed Phase 4 Interventional Results available

Pilot Study for Patients With Poor Response to Deferasirox

NCT00749515
View directory record Official record
Conditions
Transfusion-dependent Hemachromatosis, Thalassemia Major, Sickle Cell Disease
Interventions
Deferoxamine, Deferasirox, HIDA
Drug · Radiation
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Oct 16, 2026, 3:21 AM EDT
Not listed Phase 2 Interventional

Efficacy and Safety of Omega-3 Lipid Therapy in Pediatric Patients With Parenteral Nutrition-Associated Liver Disease

NCT01739517
View directory record Official record
Conditions
Short Bowel Syndrome, Cholestasis
Interventions
Omegaven Therapy
Drug
Lead sponsor
Amarnath, Rathna, M.D.
Individual
Eligibility
Up to 1 Year
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Oct 16, 2026, 3:21 AM EDT